Automated Insulin Delivery Systems Show Promise for Type 1 Diabetes Management
New data suggests automated insulin delivery (AID) systems are becoming increasingly reliable for individuals managing type 1 diabetes. Recent studies and advancements are offering improved control and a potentially simplified approach to a challenging condition that affects millions worldwide. Effective diabetes management is crucial for preventing long-term health complications.
Insulet Corporation recently presented promising study results for its tubeless, closed-loop AID system designed for adults with type 2 diabetes. The system combines continuous glucose monitoring (CGM) with automated insulin delivery, adjusting insulin levels based on real-time glucose data.
A key component of this progress is the integration of Abbott’s FreeStyle Libre® 2 Plus sensor with Insulet’s OmniPod® 5 system. This combined system is now available in Italy for people with type 1 diabetes. The technology works by using the FreeStyle Libre 2 Plus sensor to provide real-time glucose data to the OmniPod 5 app, which then calculates and delivers the appropriate insulin dosage via a catheterless insulin delivery system.
“The FreeStyle Libre technology represents a reliable, convenient, and easy-to-use solution,” said Luigi Russo, general manager of Abbott Diabetes Care Italy. “Combined with its long duration, this can help reduce some of the mental load involved in diabetes management. The collaboration with Insulet creates an additional opportunity for people with type 1 diabetes in Italy.”
Insulet was founded in 2000 by a father seeking a better way to manage his son’s type 1 diabetes, aiming to simplify insulin administration and improve the lives of those living with the condition. The company’s mission is to bring simplicity and freedom to everyone with diabetes. Insulet’s flagship product, the OmniPod, is a tubeless, wearable insulin management system.
The company reported $2.7 billion in revenue in 2025 and currently serves over 600,000 customers across 25 countries. The OmniPod 5 system is currently the most prescribed AID system in the U.S., according to data from May 2025.
These advancements in AID technology are expected to simplify daily diabetes management, reduce the uncertainty associated with insulin dosing, and contribute to better glycemic control for individuals with both type 1 and type 2 diabetes.
